Navelbine (Vinorelbine)

Vinorelbine interferes with microtubule dynamics by binding to tubulin, preventing the assembly of the mitotic spindle. This blocks cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells and ultimately reducing tumour size.

The dose of Navelbine is individualized by the prescribing oncologist based on factors such as cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. Only a qualified healthcare professional should determine the appropriate regimen.

Vinorelbine is classified as contraindicated or to be used only when the potential benefit justifies the risk to the fetus or infant. Pregnant or nursing patients should discuss alternatives with their obstetrician and oncologist, as safety data are limited.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Vinorelbine belongs to the Vinca alkaloid class, similar to vincristine and vinblastine, but it has a distinct toxicity profile with less neurotoxicity and more pronounced myelosuppression. Compared with taxanes such as paclitaxel, vinorelbine offers an oral option and may be preferred when infusion facilities are limited.

Navelbine should be stored at ambient temperature below 25 °C, protected from moisture and direct light. Keep the product in its original packaging until use, and ensure that tablets or capsules are not exposed to excessive humidity or heat to maintain potency.

Navelbine is supplied as an oral formulation that patients take with a full glass of water. It may be taken with or without food, according to the prescribing physician’s instructions, and dosing intervals are typically spaced to allow recovery of blood counts between cycles.

The most critical adverse events include severe neutropenia leading to infection, febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, and rare but serious allergic reactions. Patients should be monitored closely for signs of infection, respiratory difficulty, or hypersensitivity.

Vinorelbine is contraindicated in individuals with known hypersensitivity to vinorelbine or other Vinca alkaloids, in patients with severe bone‑marrow suppression, and in those with uncontrolled infections. Caution is also advised for patients with significant hepatic or renal impairment unless dose adjustments are made.